iShares Genomics Immunology and Healthcare ETF Rating → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free IDNA Stock Alerts $24.18 -0.09 (-0.37%) (As of 05/17/2024 ET) Add Compare Share Share RatingsStock AnalysisChartHoldingsOwnershipRatingsStock AnalysisChartHoldingsOwnershipRatings iShares Genomics Immunology and Healthcare ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.IDNA Aggregate RatingModerate Buy2.67Holdings in IDNA have an aggregate rating of Moderate Buy based on 361 analyst ratings issued in the past year covering 37 companies (75.5% of the portfolio).IDNA Aggregate Price Target$36.4150.59% UpsideHigh Prediction$53.12Average Prediction$36.41Low Prediction$23.31Holdings in IDNA have an aggregate price target of $36.41 and a range of $23.31 to $53.12 covering 37 companies (75.5% of the portfolio).IDNA Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy11 Buy rating(s)Moderate Buy16 Moderate Buy rating(s)Hold9 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by iShares Genomics Immunology and Healthcare ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 37 IDNA Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.72%SRPTSarepta Therapeutics$131.38-1.0%5 of 5 stars2.86$163.94 24.8%14Analyst UpgradePositive News5.63%RVMDRevolution Medicines$39.41+1.1%3 of 5 stars3.10$43.20 9.6%10Analyst Revision5.38%MRNAModerna$132.90+0.2%4 of 5 stars2.24$126.46 -4.8%17Analyst ForecastInsider Selling4.47%MRKMerck & Co., Inc.$131.19+0.2%5 of 5 stars2.58$131.33 0.1%12Analyst RevisionNews Coverage4.23%REGNRegeneron Pharmaceuticals$982.29+1.5%4 of 5 stars2.76$989.36 0.7%21Analyst ForecastInsider SellingNews CoveragePositive News3.58%EXELExelixis$20.91-1.5%5 of 5 stars2.59$26.13 24.9%17Analyst ForecastInsider SellingShort Interest ↑3.57%INCYIncyte$57.10+0.4%5 of 5 stars2.47$74.93 31.2%17Short Interest ↑3.40%IOVAIovance Biotherapeutics$10.24-1.8%5 of 5 stars3.00$24.64 140.6%103.24%BNTXBioNTech$90.61-2.5%1 of 5 stars2.20$111.70 23.3%10Analyst ForecastShort Interest ↑2.99%GILDGilead Sciences$67.72-0.2%5 of 5 stars2.35$83.69 23.6%172.93%TWSTTwist Bioscience$47.01+1.1%2 of 5 stars3.00$42.50 -9.6%6Gap Up2.72%SWTXSpringWorks Therapeutics$44.84+0.2%2 of 5 stars3.00$68.83 53.5%62.26%ACLXArcellx$53.62+1.6%3 of 5 stars3.08$78.73 46.8%13Analyst Forecast2.17%GERNGeron$3.81-2.3%4 of 5 stars2.80$6.10 60.1%51.89%BEAMBeam Therapeutics$24.62+3.5%1 of 5 stars2.38$40.18 63.2%13Short Interest ↑1.85%DVAXDynavax Technologies$11.11-1.5%4 of 5 stars2.75$25.33 128.0%4Short Interest ↑Analyst Revision1.51%DNAGinkgo Bioworks$0.81-3.6%2 of 5 stars1.67$1.90 135.8%6Analyst ForecastInsider BuyingShort Interest ↑News Coverage1.50%DCPHDeciphera Pharmaceuticals$25.46+0.0%3 of 5 stars2.30$24.17 -5.1%101.48%LGNDLigand Pharmaceuticals$86.06+1.2%5 of 5 stars3.00$116.33 35.2%3Insider SellingNews Coverage1.42%BPMCBlueprint Medicines$104.96-1.6%1 of 5 stars2.53$102.65 -2.2%17Analyst ForecastShort Interest ↑Analyst Revision1.33%IBRXImmunityBio$7.65-1.3%0 of 5 stars2.00$6.00 -21.6%11.28%BCRXBioCryst Pharmaceuticals$6.28-2.9%4 of 5 stars3.00$14.00 122.9%7Insider BuyingPositive News1.18%FDMT4D Molecular Therapeutics$25.34-1.2%2 of 5 stars3.00$44.22 74.5%10Earnings ReportAnalyst Revision1.15%MGNXMacroGenics$4.37-14.7%4 of 5 stars2.60$13.67 213.1%10Analyst Revision1.07%VIRVir Biotechnology$9.73-2.0%2 of 5 stars2.57$33.57 245.0%70.99%ABCLAbCellera Biologics$3.64-3.7%2 of 5 stars3.00$16.17 344.1%70.93%CRSPCRISPR Therapeutics$56.22+1.0%3 of 5 stars2.35$73.93 31.5%17Gap Up0.92%RCUSArcus Biosciences$16.90-3.2%1 of 5 stars2.88$41.25 144.1%80.82%ARCTArcturus Therapeutics$29.78-2.4%2 of 5 stars3.00$64.86 117.8%7Short Interest ↑News Coverage0.77%NRIXNurix Therapeutics$16.59+7.7%2 of 5 stars2.88$21.88 31.9%8Analyst ForecastNews CoverageHigh Trading Volume0.62%NVAXNovavax$13.01-9.7%2 of 5 stars2.40$14.00 7.6%5Earnings ReportInsider Selling0.56%EDITEditas Medicine$5.62-4.6%4 of 5 stars2.50$13.90 147.3%10Insider BuyingShort Interest ↑0.53%OABIOmniAb$4.45-2.2%2 of 5 stars3.00$9.00 102.2%4Analyst Forecast0.46%NTLAIntellia Therapeutics$26.22+0.2%4 of 5 stars2.69$66.77 154.7%13Gap Up0.33%CRBUCaribou Biosciences$3.39-5.6%2 of 5 stars2.75$21.50 534.2%4Analyst ForecastShort Interest ↓News Coverage0.32%XNCRXencor$23.03+2.5%4 of 5 stars2.88$36.25 57.4%8Gap Up0.25%QUREuniQure$5.01-1.2%2 of 5 stars2.71$26.67 432.3%7 This page (NYSEARCA:IDNA) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsNext President (Not Trump. Not Biden.)The Freeport Society4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares Genomics Immunology and Healthcare ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
